Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs

Mauro Gori, Maurizio Volterrani, Massimo F. Piepoli, Michele Senni

Research output: Contribution to journalArticle

Abstract

Sacubritil. *. valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.

Original languageEnglish
Pages (from-to)136-140
JournalInternational Journal of Cardiology
Volume226
DOIs
Publication statusPublished - Jan 2017

Keywords

  • Angiotensin receptor-neprilysin inhibitor
  • ARNi
  • Heart failure
  • LCZ696

ASJC Scopus subject areas

  • Medicine(all)
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs'. Together they form a unique fingerprint.

  • Cite this